Karolinska Development AB (KDEV.ST) Quote| Reuters.com
Edition:
United States

Karolinska Development AB (KDEV.ST)

KDEV.ST on Stockholm Stock Exchange

7.25SEK
23 Jun 2016
Change (% chg)

0.05kr (+0.69%)
Prev Close
7.20kr
Open
7.15kr
Day's High
7.25kr
Day's Low
7.15kr
Volume
4,080
Avg. Vol
23,760
52-wk High
13.60kr
52-wk Low
6.65kr

KDEV.ST

Chart for KDEV.ST

About

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical... (more)

Overall

Beta: 0.60
Market Cap(Mil.): kr376.61
Shares Outstanding(Mil.): 51.95
Dividend: --
Yield (%): --

Financials

  KDEV.ST Industry Sector
P/E (TTM): -- 46.71 34.11
EPS (TTM): -17.01 -- --
ROI: -95.33 11.65 14.23
ROE: -150.63 13.64 15.46

BRIEF-Karolinska Development: Lipidor and Cadila Pharmaceuticals agree on Phase III study and sale of Psoriasis product

* Lipidor and Cadila Pharmaceuticals announce agreement on Phase III clinical study and joint commercialization of topical Psoriasis product

Jun 01 2016

BRIEF-Karolinska Development Q1 net sales fall to SEK 0.6 million

* Q1 net sales 0.6 million Swedish crowns ($75,000) versus 1 million crowns year ago

May 10 2016

BRIEF-Karolinska Development portfolio company Aprea raises SEK 437 mln

* Its portfolio company Aprea raises 437 million Swedish crowns ($51.44 million)

Mar 09 2016

BRIEF-Karolinska Development: Akinion halts development of AKN-028 due to safety concerns

* Portfolio company Akinion halts further development of AKN-028 due to safety concerns

Mar 04 2016

BRIEF-Karolinska Development's Dilaforette signs agreement with Arabian Gulf University

* Karolinska Development announces that its portfolio company Dilaforette AB, a company focused on innovative treatments for patients with sickle-cell disease, and Arabian Gulf University (AGU) in Bahrain, have signed a Clinical Collaboration agreement for the Phase 2 proof of concept trial of sevuparin in patients with Sickle Cell Disease (SCD) experiencing acute Vaso-Occlusive Crisis (VOC)

Feb 16 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.